Peripartum Cardiomyopathy

On rare occasions, pregnancy can lead to a condition called peripartum cardiomyopathy, or pregnancy-associated heart failure. Peripartum cardiomyopathy is a form of dilated cardiomyopathy. (Cardiomyopathy means heart muscle weakness.)

Pregnant woman in hospital gown
Tetra Images / Brand X Pictures / Getty Images 

Women who develop peripartum cardiomyopathy experience the onset of heart failure either during the last month of pregnancy or within five months after delivering a baby. ("Peripartum" means “around the time of childbirth.”)

Women who develop this condition usually have no prior underlying heart disease, and no other identifiable reason to develop heart disease. Their heart failure can be a temporary, self-limited condition, or can progress to permanent, severe, life-threatening heart failure.

What Causes Peripartum Cardiomyopathy?

The cause of peripartum cardiomyopathy is not fully known. There is evidence that inflammation of the heart muscle (also called myocarditis) may play an important role, and may be related to inflammatory proteins that sometimes can be found in the blood during pregnancy.

There is also evidence that fetal cells that occasionally escape into the mother's bloodstream can cause an immune reaction, leading to myocarditis. Furthermore, there may be a genetic predisposition to peripartum cardiomyopathy in some families. 

In recent years evidence has accumulated that peripartum cardiomyopathy (as well as another disorder of pregnancy called preeclampsia) may be due to something called “angiogenic imbalance.” Angiogenic imbalance refers to the escape into the maternal circulation of substances formed in the placenta that partially block vascular endothelial growth factor (VEGF) in the mother.

A lack of sufficient VEGF can prevent the mother’s blood vessels from completely repairing themselves during the normal wear and tear of life. The concept of angiogenic imbalance may offer a fruitful avenue of research for developing therapies to treat or prevent peripartum cardiomyopathy and other disorders of pregnancy.

Who Gets It?

While peripartum cardiomyopathy is thankfully a rare condition (occurring in about 1 of 4,000 deliveries in the U.S.), some women seem to be at higher risk than others.

Risk factors for peripartum cardiomyopathy include: age over 30 years, having delivered children before, pregnancy with multiple fetuses, African descent, a history of preeclampsia or postpartum hypertension, a history of prior peripartum cardiomyopathy, or cocaine abuse.


Since peripartum cardiomyopathy leads to heart failure, the symptoms are essentially the same as for most other forms of heart failure. These symptoms of heart failure most commonly include dyspnea, orthopnea, paroxysmal nocturnal dyspnea, and fluid retention.


With a few notable exceptions, peripartum cardiomyopathy is similar to the treatment of any form of dilated cardiomyopathy.

The notable exceptions to "standard" heart failure treatment come into play when heart failure occurs before the baby is delivered. Some of the "routine" treatments for heart failure should be withheld until delivery.

Specifically, ACE inhibitors such as Vasotec (enalapril), which are drugs that dilate blood vessels, should not be used during pregnancy, since these drugs can adversely affect the fetus. Instead, hydralazine can be substituted as a blood vessel dilator until delivery has occurred.

Similarly, the drugs spironolactone and Inspra (eplerenone)—the so-called aldosterone antagonists, which can help treat some patients with dilated cardiomyopathy—have not been tested during pregnancy, and should be avoided.

Recently, preliminary evidence has been reported suggesting that women with peripartum cardiomyopathy might benefit from the drug bromocriptine—a drug used to treat a variety of disorders including Parkinson's disease and hyperprolactinemia.

Bromocriptine is not a completely benign drug, however (among other things, it stops lactation), and more extensive clinical trials will be necessary before it can be generally recommended.

Overall, the prognosis of women who have peripartum cardiomyopathy appears to be somewhat better than for women who have other types of cardiomyopathy.

In some studies, as many as 60 percent of the women with this condition have made a complete recovery. Still, the mortality rate with peripartum cardiomyopathy is as high as 10 percent after two years.

Long-Term Considerations

It is especially important to know that women who have had peripartum cardiomyopathy—even the women who seem to have made a complete recovery—are at particularly high risk of developing the condition again with subsequent pregnancies.

And if peripartum cardiomyopathy occurs for a second time, the risk of more permanent and severe cardiac damage becomes very high.

So once a woman has had peripartum cardiomyopathy, it is important to take steps to avoid becoming pregnant again.

A Word From Verywell

Peripartum cardiomyopathy is a serious cardiac condition that produces heart failure during late-term pregnancy or shortly after delivery. While treatment is available that helps the majority of affected women recover, it is still a dangerous cardiac problem that produces a substantial rate of disability and death. Women who have had this condition are at high risk of having a recurrence with subsequent pregnancies.

4 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. Okeke T, Ezenyeaku C, Ikeako L. Peripartum cardiomyopathy. Ann Med Health Sci Res. 2013;3(3):313-9. doi: 10.4103/2141-9248.117925

  2. Krejci J, Mlejnek D, Sochorova D, Nemec P. Inflammatory Cardiomyopathy: A Current View on the Pathophysiology, Diagnosis, and Treatment. Biomed Res Int. 2016;2016:4087632. doi: 10.1155/2016/4087632

  3. Patten IS, Rana S, Shahul S, et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature. 2012;485(7398):333-8. doi: 10.1038/nature11040

  4. Koenig T, Hilfiker-kleiner D, Bauersachs J. Peripartum cardiomyopathy. Herz. 2018;43(5):431-437. doi: 10.1007/s00059-018-4709-z

Additional Reading

By Richard N. Fogoros, MD
Richard N. Fogoros, MD, is a retired professor of medicine and board-certified in internal medicine, clinical cardiology, and clinical electrophysiology.